Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6538
    +0.0015 (+0.23%)
     

  • OIL

    84.04
    +0.47 (+0.56%)
     

  • GOLD

    2,359.60
    +17.10 (+0.73%)
     

  • Bitcoin AUD

    98,213.51
    +899.16 (+0.92%)
     

  • CMC Crypto 200

    1,384.26
    -12.28 (-0.88%)
     

  • AUD/EUR

    0.6091
    +0.0018 (+0.29%)
     

  • AUD/NZD

    1.0986
    +0.0028 (+0.26%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,112.92
    +34.06 (+0.42%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,049.07
    +131.79 (+0.74%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Acerus Announces Resignation of Director

Acerus Pharmaceuticals Corporation
·1-min read
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corporation

TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately.

About Acerus

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Company Contact
Naveed Manzoor
Chief Financial Officer
ir@aceruspharma.com